The Molecular Influenza Diagnostic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Molecular Influenza Diagnostic market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Molecular Influenza Diagnostic global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Reverse Transcription Polymerase Chain Reaction (RT-PCR) segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Molecular Influenza Diagnostic include BD, Abbott (Include Alere), Roche, SIEMENS, and Analytik Jena, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Molecular Influenza Diagnostic market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Nucleic Acid Sequence Based Amplification (NASBA) Tests
Loop-mediated Isothermal Amplification-Based Assays (LAMP)
Simple Amplification-based Assays (SAMBA)
Market segment by Application, can be divided into
Hospitals
POCT
Others
Market segment by players, this report covers
BD
Abbott (Include Alere)
Roche
SIEMENS
Analytik Jena
Quidel
Thermo Fisher
Meridian Bioscience
BioMerieux
Sekisui Diagnostics
Response Biomedical
SA Scientific
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Molecular Influenza Diagnostic product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Molecular Influenza Diagnostic, with revenue, gross margin and global market share of Molecular Influenza Diagnostic from 2019 to 2022.
Chapter 3, the Molecular Influenza Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Molecular Influenza Diagnostic market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Molecular Influenza Diagnostic research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Molecular Influenza Diagnostic
1.2 Classification of Molecular Influenza Diagnostic by Type
1.2.1 Overview: Global Molecular Influenza Diagnostic Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Molecular Influenza Diagnostic Revenue Market Share by Type in 2021
1.2.3 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
1.2.4 Nucleic Acid Sequence Based Amplification (NASBA) Tests
1.2.5 Loop-mediated Isothermal Amplification-Based Assays (LAMP)
1.2.6 Simple Amplification-based Assays (SAMBA)
1.3 Global Molecular Influenza Diagnostic Market by Application
1.3.1 Overview: Global Molecular Influenza Diagnostic Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 POCT
1.3.4 Others
1.4 Global Molecular Influenza Diagnostic Market Size & Forecast
1.5 Global Molecular Influenza Diagnostic Market Size and Forecast by Region
1.5.1 Global Molecular Influenza Diagnostic Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Molecular Influenza Diagnostic Market Size by Region, (2017-2022)
1.5.3 North America Molecular Influenza Diagnostic Market Size and Prospect (2017-2028)
1.5.4 Europe Molecular Influenza Diagnostic Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Molecular Influenza Diagnostic Market Size and Prospect (2017-2028)
1.5.6 South America Molecular Influenza Diagnostic Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Molecular Influenza Diagnostic Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Molecular Influenza Diagnostic Market Drivers
1.6.2 Molecular Influenza Diagnostic Market Restraints
1.6.3 Molecular Influenza Diagnostic Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 BD
2.1.1 BD Details
2.1.2 BD Major Business
2.1.3 BD Molecular Influenza Diagnostic Product and Solutions
2.1.4 BD Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 BD Recent Developments and Future Plans
2.2 Abbott (Include Alere)
2.2.1 Abbott (Include Alere) Details
2.2.2 Abbott (Include Alere) Major Business
2.2.3 Abbott (Include Alere) Molecular Influenza Diagnostic Product and Solutions
2.2.4 Abbott (Include Alere) Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Abbott (Include Alere) Recent Developments and Future Plans
2.3 Roche
2.3.1 Roche Details
2.3.2 Roche Major Business
2.3.3 Roche Molecular Influenza Diagnostic Product and Solutions
2.3.4 Roche Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Roche Recent Developments and Future Plans
2.4 SIEMENS
2.4.1 SIEMENS Details
2.4.2 SIEMENS Major Business
2.4.3 SIEMENS Molecular Influenza Diagnostic Product and Solutions
2.4.4 SIEMENS Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 SIEMENS Recent Developments and Future Plans
2.5 Analytik Jena
2.5.1 Analytik Jena Details
2.5.2 Analytik Jena Major Business
2.5.3 Analytik Jena Molecular Influenza Diagnostic Product and Solutions
2.5.4 Analytik Jena Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Analytik Jena Recent Developments and Future Plans
2.6 Quidel
2.6.1 Quidel Details
2.6.2 Quidel Major Business
2.6.3 Quidel Molecular Influenza Diagnostic Product and Solutions
2.6.4 Quidel Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Quidel Recent Developments and Future Plans
2.7 Thermo Fisher
2.7.1 Thermo Fisher Details
2.7.2 Thermo Fisher Major Business
2.7.3 Thermo Fisher Molecular Influenza Diagnostic Product and Solutions
2.7.4 Thermo Fisher Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Thermo Fisher Recent Developments and Future Plans
2.8 Meridian Bioscience
2.8.1 Meridian Bioscience Details
2.8.2 Meridian Bioscience Major Business
2.8.3 Meridian Bioscience Molecular Influenza Diagnostic Product and Solutions
2.8.4 Meridian Bioscience Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Meridian Bioscience Recent Developments and Future Plans
2.9 BioMerieux
2.9.1 BioMerieux Details
2.9.2 BioMerieux Major Business
2.9.3 BioMerieux Molecular Influenza Diagnostic Product and Solutions
2.9.4 BioMerieux Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 BioMerieux Recent Developments and Future Plans
2.10 Sekisui Diagnostics
2.10.1 Sekisui Diagnostics Details
2.10.2 Sekisui Diagnostics Major Business
2.10.3 Sekisui Diagnostics Molecular Influenza Diagnostic Product and Solutions
2.10.4 Sekisui Diagnostics Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Sekisui Diagnostics Recent Developments and Future Plans
2.11 Response Biomedical
2.11.1 Response Biomedical Details
2.11.2 Response Biomedical Major Business
2.11.3 Response Biomedical Molecular Influenza Diagnostic Product and Solutions
2.11.4 Response Biomedical Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Response Biomedical Recent Developments and Future Plans
2.12 SA Scientific
2.12.1 SA Scientific Details
2.12.2 SA Scientific Major Business
2.12.3 SA Scientific Molecular Influenza Diagnostic Product and Solutions
2.12.4 SA Scientific Molecular Influenza Diagnostic Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 SA Scientific Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Molecular Influenza Diagnostic Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Molecular Influenza Diagnostic Players Market Share in 2021
3.2.2 Top 10 Molecular Influenza Diagnostic Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Molecular Influenza Diagnostic Players Head Office, Products and Services Provided
3.4 Molecular Influenza Diagnostic Mergers & Acquisitions
3.5 Molecular Influenza Diagnostic New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Molecular Influenza Diagnostic Revenue and Market Share by Type (2017-2022)
4.2 Global Molecular Influenza Diagnostic Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Molecular Influenza Diagnostic Revenue Market Share by Application (2017-2022)
5.2 Global Molecular Influenza Diagnostic Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Molecular Influenza Diagnostic Revenue by Type (2017-2028)
6.2 North America Molecular Influenza Diagnostic Revenue by Application (2017-2028)
6.3 North America Molecular Influenza Diagnostic Market Size by Country
6.3.1 North America Molecular Influenza Diagnostic Revenue by Country (2017-2028)
6.3.2 United States Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
6.3.3 Canada Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
6.3.4 Mexico Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Molecular Influenza Diagnostic Revenue by Type (2017-2028)
7.2 Europe Molecular Influenza Diagnostic Revenue by Application (2017-2028)
7.3 Europe Molecular Influenza Diagnostic Market Size by Country
7.3.1 Europe Molecular Influenza Diagnostic Revenue by Country (2017-2028)
7.3.2 Germany Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
7.3.3 France Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
7.3.5 Russia Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
7.3.6 Italy Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Molecular Influenza Diagnostic Revenue by Type (2017-2028)
8.2 Asia-Pacific Molecular Influenza Diagnostic Revenue by Application (2017-2028)
8.3 Asia-Pacific Molecular Influenza Diagnostic Market Size by Region
8.3.1 Asia-Pacific Molecular Influenza Diagnostic Revenue by Region (2017-2028)
8.3.2 China Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8.3.3 Japan Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8.3.4 South Korea Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8.3.5 India Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
8.3.7 Australia Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Molecular Influenza Diagnostic Revenue by Type (2017-2028)
9.2 South America Molecular Influenza Diagnostic Revenue by Application (2017-2028)
9.3 South America Molecular Influenza Diagnostic Market Size by Country
9.3.1 South America Molecular Influenza Diagnostic Revenue by Country (2017-2028)
9.3.2 Brazil Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
9.3.3 Argentina Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Molecular Influenza Diagnostic Revenue by Type (2017-2028)
10.2 Middle East & Africa Molecular Influenza Diagnostic Revenue by Application (2017-2028)
10.3 Middle East & Africa Molecular Influenza Diagnostic Market Size by Country
10.3.1 Middle East & Africa Molecular Influenza Diagnostic Revenue by Country (2017-2028)
10.3.2 Turkey Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
10.3.4 UAE Molecular Influenza Diagnostic Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Molecular Influenza Diagnostic Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Molecular Influenza Diagnostic Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Molecular Influenza Diagnostic Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Molecular Influenza Diagnostic Revenue (USD Million) by Region (2017-2022)
Table 5. Global Molecular Influenza Diagnostic Revenue Market Share by Region (2023-2028)
Table 6. BD Corporate Information, Head Office, and Major Competitors
Table 7. BD Major Business
Table 8. BD Molecular Influenza Diagnostic Product and Solutions
Table 9. BD Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Abbott (Include Alere) Corporate Information, Head Office, and Major Competitors
Table 11. Abbott (Include Alere) Major Business
Table 12. Abbott (Include Alere) Molecular Influenza Diagnostic Product and Solutions
Table 13. Abbott (Include Alere) Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Roche Corporate Information, Head Office, and Major Competitors
Table 15. Roche Major Business
Table 16. Roche Molecular Influenza Diagnostic Product and Solutions
Table 17. Roche Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. SIEMENS Corporate Information, Head Office, and Major Competitors
Table 19. SIEMENS Major Business
Table 20. SIEMENS Molecular Influenza Diagnostic Product and Solutions
Table 21. SIEMENS Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Analytik Jena Corporate Information, Head Office, and Major Competitors
Table 23. Analytik Jena Major Business
Table 24. Analytik Jena Molecular Influenza Diagnostic Product and Solutions
Table 25. Analytik Jena Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Quidel Corporate Information, Head Office, and Major Competitors
Table 27. Quidel Major Business
Table 28. Quidel Molecular Influenza Diagnostic Product and Solutions
Table 29. Quidel Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Thermo Fisher Corporate Information, Head Office, and Major Competitors
Table 31. Thermo Fisher Major Business
Table 32. Thermo Fisher Molecular Influenza Diagnostic Product and Solutions
Table 33. Thermo Fisher Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Meridian Bioscience Corporate Information, Head Office, and Major Competitors
Table 35. Meridian Bioscience Major Business
Table 36. Meridian Bioscience Molecular Influenza Diagnostic Product and Solutions
Table 37. Meridian Bioscience Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. BioMerieux Corporate Information, Head Office, and Major Competitors
Table 39. BioMerieux Major Business
Table 40. BioMerieux Molecular Influenza Diagnostic Product and Solutions
Table 41. BioMerieux Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Sekisui Diagnostics Corporate Information, Head Office, and Major Competitors
Table 43. Sekisui Diagnostics Major Business
Table 44. Sekisui Diagnostics Molecular Influenza Diagnostic Product and Solutions
Table 45. Sekisui Diagnostics Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Response Biomedical Corporate Information, Head Office, and Major Competitors
Table 47. Response Biomedical Major Business
Table 48. Response Biomedical Molecular Influenza Diagnostic Product and Solutions
Table 49. Response Biomedical Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. SA Scientific Corporate Information, Head Office, and Major Competitors
Table 51. SA Scientific Major Business
Table 52. SA Scientific Molecular Influenza Diagnostic Product and Solutions
Table 53. SA Scientific Molecular Influenza Diagnostic Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Global Molecular Influenza Diagnostic Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 55. Global Molecular Influenza Diagnostic Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 56. Breakdown of Molecular Influenza Diagnostic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Molecular Influenza Diagnostic Players Head Office, Products and Services Provided
Table 58. Molecular Influenza Diagnostic Mergers & Acquisitions in the Past Five Years
Table 59. Molecular Influenza Diagnostic New Entrants and Expansion Plans
Table 60. Global Molecular Influenza Diagnostic Revenue (USD Million) by Type (2017-2022)
Table 61. Global Molecular Influenza Diagnostic Revenue Share by Type (2017-2022)
Table 62. Global Molecular Influenza Diagnostic Revenue Forecast by Type (2023-2028)
Table 63. Global Molecular Influenza Diagnostic Revenue by Application (2017-2022)
Table 64. Global Molecular Influenza Diagnostic Revenue Forecast by Application (2023-2028)
Table 65. North America Molecular Influenza Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 66. North America Molecular Influenza Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 67. North America Molecular Influenza Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 68. North America Molecular Influenza Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 69. North America Molecular Influenza Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 70. North America Molecular Influenza Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 71. Europe Molecular Influenza Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 72. Europe Molecular Influenza Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 73. Europe Molecular Influenza Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 74. Europe Molecular Influenza Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 75. Europe Molecular Influenza Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 76. Europe Molecular Influenza Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 77. Asia-Pacific Molecular Influenza Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 78. Asia-Pacific Molecular Influenza Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 79. Asia-Pacific Molecular Influenza Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 80. Asia-Pacific Molecular Influenza Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 81. Asia-Pacific Molecular Influenza Diagnostic Revenue by Region (2017-2022) & (USD Million)
Table 82. Asia-Pacific Molecular Influenza Diagnostic Revenue by Region (2023-2028) & (USD Million)
Table 83. South America Molecular Influenza Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 84. South America Molecular Influenza Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 85. South America Molecular Influenza Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 86. South America Molecular Influenza Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 87. South America Molecular Influenza Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 88. South America Molecular Influenza Diagnostic Revenue by Country (2023-2028) & (USD Million)
Table 89. Middle East & Africa Molecular Influenza Diagnostic Revenue by Type (2017-2022) & (USD Million)
Table 90. Middle East & Africa Molecular Influenza Diagnostic Revenue by Type (2023-2028) & (USD Million)
Table 91. Middle East & Africa Molecular Influenza Diagnostic Revenue by Application (2017-2022) & (USD Million)
Table 92. Middle East & Africa Molecular Influenza Diagnostic Revenue by Application (2023-2028) & (USD Million)
Table 93. Middle East & Africa Molecular Influenza Diagnostic Revenue by Country (2017-2022) & (USD Million)
Table 94. Middle East & Africa Molecular Influenza Diagnostic Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Molecular Influenza Diagnostic Picture
Figure 2. Global Molecular Influenza Diagnostic Revenue Market Share by Type in 2021
Figure 3. Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Figure 4. Nucleic Acid Sequence Based Amplification (NASBA) Tests
Figure 5. Loop-mediated Isothermal Amplification-Based Assays (LAMP)
Figure 6. Simple Amplification-based Assays (SAMBA)
Figure 7. Molecular Influenza Diagnostic Revenue Market Share by Application in 2021
Figure 8. Hospitals Picture
Figure 9. POCT Picture
Figure 10. Others Picture
Figure 11. Global Molecular Influenza Diagnostic Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 12. Global Molecular Influenza Diagnostic Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Molecular Influenza Diagnostic Revenue Market Share by Region (2017-2028)
Figure 14. Global Molecular Influenza Diagnostic Revenue Market Share by Region in 2021
Figure 15. North America Molecular Influenza Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. Europe Molecular Influenza Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Asia-Pacific Molecular Influenza Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. South America Molecular Influenza Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Middle East and Africa Molecular Influenza Diagnostic Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Molecular Influenza Diagnostic Market Drivers
Figure 21. Molecular Influenza Diagnostic Market Restraints
Figure 22. Molecular Influenza Diagnostic Market Trends
Figure 23. BD Recent Developments and Future Plans
Figure 24. Abbott (Include Alere) Recent Developments and Future Plans
Figure 25. Roche Recent Developments and Future Plans
Figure 26. SIEMENS Recent Developments and Future Plans
Figure 27. Analytik Jena Recent Developments and Future Plans
Figure 28. Quidel Recent Developments and Future Plans
Figure 29. Thermo Fisher Recent Developments and Future Plans
Figure 30. Meridian Bioscience Recent Developments and Future Plans
Figure 31. BioMerieux Recent Developments and Future Plans
Figure 32. Sekisui Diagnostics Recent Developments and Future Plans
Figure 33. Response Biomedical Recent Developments and Future Plans
Figure 34. SA Scientific Recent Developments and Future Plans
Figure 35. Global Molecular Influenza Diagnostic Revenue Share by Players in 2021
Figure 36. Molecular Influenza Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 37. Global Top 3 Players Molecular Influenza Diagnostic Revenue Market Share in 2021
Figure 38. Global Top 10 Players Molecular Influenza Diagnostic Revenue Market Share in 2021
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 40. Global Molecular Influenza Diagnostic Revenue Share by Type in 2021
Figure 41. Global Molecular Influenza Diagnostic Market Share Forecast by Type (2023-2028)
Figure 42. Global Molecular Influenza Diagnostic Revenue Share by Application in 2021
Figure 43. Global Molecular Influenza Diagnostic Market Share Forecast by Application (2023-2028)
Figure 44. North America Molecular Influenza Diagnostic Sales Market Share by Type (2017-2028)
Figure 45. North America Molecular Influenza Diagnostic Sales Market Share by Application (2017-2028)
Figure 46. North America Molecular Influenza Diagnostic Revenue Market Share by Country (2017-2028)
Figure 47. United States Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. Canada Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Mexico Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Europe Molecular Influenza Diagnostic Sales Market Share by Type (2017-2028)
Figure 51. Europe Molecular Influenza Diagnostic Sales Market Share by Application (2017-2028)
Figure 52. Europe Molecular Influenza Diagnostic Revenue Market Share by Country (2017-2028)
Figure 53. Germany Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. France Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 55. United Kingdom Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Russia Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Italy Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Asia-Pacific Molecular Influenza Diagnostic Sales Market Share by Type (2017-2028)
Figure 59. Asia-Pacific Molecular Influenza Diagnostic Sales Market Share by Application (2017-2028)
Figure 60. Asia-Pacific Molecular Influenza Diagnostic Revenue Market Share by Region (2017-2028)
Figure 61. China Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Japan Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South Korea Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. India Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Southeast Asia Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Australia Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. South America Molecular Influenza Diagnostic Sales Market Share by Type (2017-2028)
Figure 68. South America Molecular Influenza Diagnostic Sales Market Share by Application (2017-2028)
Figure 69. South America Molecular Influenza Diagnostic Revenue Market Share by Country (2017-2028)
Figure 70. Brazil Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Argentina Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Middle East and Africa Molecular Influenza Diagnostic Sales Market Share by Type (2017-2028)
Figure 73. Middle East and Africa Molecular Influenza Diagnostic Sales Market Share by Application (2017-2028)
Figure 74. Middle East and Africa Molecular Influenza Diagnostic Revenue Market Share by Country (2017-2028)
Figure 75. Turkey Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. UAE Molecular Influenza Diagnostic Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source